[1] Lai E, Astara G, Ziranu P, et al. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? Crit Rev Oncol Hematol,2021,157:103167. [2] Mou SJ, Yang PF, Liu YP, et al. BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci,2020,242:117177. [3] Jia Y, Zhang W, You S, et al. A nomogram for predicting depression in patients with hepatocellular carcinoma: an observational cross-sectional study. Int J Psychiatry Clin Pract,2019,23:273-280. [4] Yu X, Li M, Cui M, et al. Silence of yki by miR-7 regulates the Hippo pathway. Biochem Biophys Res Commun,2020,532:446-452. [5] Kulkarni A, Chang MT, Vissers JHA, et al. The Hippo Pathway as a Driver of Select Human Cancers. Trends Cancer, 2020, 6:781-796. [6] Sarmasti Emami S, Zhang D, Yang X. Interaction of the Hippo Pathway and Phosphatases in Tumorigenesis. Cancers (Basel),2020,12:2438 [7] Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell,2018,173:321-337. [8] Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr biol,2007,17:2054-2060. [9] Fitamant J, Kottakis F, Benhamouche S, et al. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Rep,2015,10:1692-1707. [10] Tschaharganeh DF, Chen X, Latzko P, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology,2013,144:15301542. [11] Kim W, Khan SK, Yang Y. Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation. BMB Rep,2017,50:1-2. [12] Wang C, Zhu ZM, Cheng LL, et al. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells. Molecular medicine reports,2015,11: 4101-4108. [13] Wang J, Ma L, Weng W, et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology, 2013,58:1011-1020. [14] Li L, Wang J, Zhang Y, et al. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS lett,2013,587:3921-3927. [15] Yi C, Shen Z, Stemmer-Rachamimov A, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.Sci signal,2013,6: ra77. [16] Hermann A, Wennmann DO, Gromnitza S, et al. WW and C2 domain-containing proteins regulate hepatic cell differentiation and tumorigenesis through the hippo signaling pathway. Hepatology,2018,67:1546-1559. [17] B Mao, F Hu, J Cheng, et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene,2014,33: 1468-1474. |